Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson’s disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mechanistic disease stratification will be crucial to develop a precision medicine approach for future disease modifying therapy in sporadic Parkinson's disease (sPD). Mitochondrial and lysosomal dysfunction are key mechanisms in the pathogenesis of sPD and therefore promising targets for therapeutic intervention. We investigated mitochondrial and lysosomal function in skin fibroblasts of 100 sPD patients and 50 age-matched controls. A combination of cellular assays, RNA-seq based pathway analysis and genotyping was applied. Distinct subgroups with mitochondrial (mito-sPD) or lysosomal (lyso-sPD) dysfunction were identified. Mitochondrial dysfunction correlated with reduction in complex I and IV protein levels. RNA-seq based pathway analysis revealed marked activation of the lysosomal pathway with enrichment for lysosomal disease gene variants in lyso-sPD. Conversion of fibroblasts to induced neuronal progenitor cells and subsequent differentiation into tyrosine hydroxylase positive neurons confirmed and further enhanced both mitochondrial and lysosomal abnormalities. Treatment with ursodeoxycholic acid improved mitochondrial membrane potential and intracellular ATP levels even in sPD patient fibroblast lines with comparatively mild mitochondrial dysfunction. The results of our study suggest that in-depth phenotyping and focussed assessment of putative neuroprotective compounds in peripheral tissue are a promising approach towards disease stratification and precision medicine in sPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433
Self-citationMeyer, K., Ferraiuolo, L., Miranda, C. J., Likhite, S., McElroy, S., Renusch, S., Ditsworth, D., Lagier-Tourenne, C., Smith, R. A., Ravits, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314085111 · Cited by 361
Self-citationPromises, promises, and precision medicine
Joyner, M. J., & Paneth, N. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126119 · Cited by 171
Bonello, F., Hassoun, S.-M., Mouton-Liger, F., Shin, Y. S., Muscat, A., Tesson, C., Lesage, S., Beart, P. M., Brice, A., Krupp, J., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz004 · Cited by 163
Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M. P., & Gama, M. J. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8295-4 · Cited by 156 · cited 1×
“UDCA and its taurine conjugate tauroursodeoxycholic acid (TUDCA) are thought to exert a neuroprotective effect via Akt activation (Castro-Caldas et al., 2012; Chun and Low, 2012; Mortiboys et al., 2013).”
BackgroundUDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo
Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., & Bandmann, O. (2015) · Neurology · doi:10.1212/wnl.0000000000001905 · Cited by 131 · cited 3×
“The beneficial effect of UDCA in sPD patient tissue reported here is comparable to the effect we previously observed in genetically stratified PD patient tissue (Mortiboys et al., 2013; Mortiboys et al., 2015).”
BackgroundResultSelf-citation
Cited by
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,019
Mitochondrial dysfunction and mitophagy in parkinson’s disease: from mechanism to therapy
Malpartida, A. B., Williamson, M., Narendra, D. P., Wade-Martins, R., & Ryan, B. J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.007 · Cited by 482
Self-citationProgress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Self-citationPayne, T., Appleby, M., Buckley, E., van Gelder, L. M. A., Mullish, B. H., Sassani, M., Dunning, M. J., Hernandez, D., Scholz, S. W., McNeill, A., et al. (2023) · Movement Disorders · doi:10.1002/mds.29450 · Cited by 76
Self-citationCuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Metadata
- Authors
- Carling, P. J., Mortiboys, H., Green, C., Mihaylov, S., Sandor, C., Schwartzentruber, A., Taylor, R., Wei, W., Hastings, C., Wong, S., Lo, C., Evetts, S., Clemmens, H., Wyles, M., Willcox, S., Payne, T., Hughes, R., Ferraiuolo, L., Webber, C., Hide, W., Wade-Martins, R., Talbot, K., Hu, M. T., & Bandmann, O.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 187
- Pages
- 101772
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W3005814496
- Cited by
- 49
- References
- 6
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson’s disease. https://app.cochat.ai/papers/10.1016/j.pneurobio.2020.101772
- The paper
- Carling, P. J., Mortiboys, H., Green, C., Mihaylov, S., Sandor, C., Schwartzentruber, A., Taylor, R., Wei, W., Hastings, C., Wong, S., Lo, C., Evetts, S., Clemmens, H., Wyles, M., Willcox, S., Payne, T., Hughes, R., Ferraiuolo, L., Webber, C., . . . Bandmann, O. (2020). Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson’s disease. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2020.101772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.